Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial

Chen, Jie; Li, Chen; Cao, Yanguang; Zhu, Li; Zhang, Bailin; You, Jie; Hou, Huilian; Wang, Jing

doi:10.1186/s12885-022-09866-w

Cited by 5 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of chemoradiotherapy and immunotherapy is currently under investigation in a phase-II clinical trial with patients with locally advanced cervical cancer [ 47 ]. For patients with lung squamous cell carcinoma, the combination of chemotherapy with radiotherapy resulted in a longer overall survival and progression-free survival; however, this strategy increased the risk of gastrointestinal abnormalities, hematoxicity, and liver dysfunction [ 47 ]. For patients with non-metastatic and metastatic esophageal cancer, neoadjuvant chemoradiotherapy and immunotherapy have no effect on the survival benefits [ 48 ].…”

Section: Strategies To Turn Non-inflamed Cold Tumors Into Inflamed Ho...mentioning

confidence: 99%

Lighting Up the Fire in the Microenvironment of Cold Tumors: A Major Challenge to Improve Cancer Immunotherapy

Benoit

Vogin

Duhem

et al. 2023

Cells

View full text Add to dashboard Cite

Immunotherapy includes immune checkpoint inhibitors (ICI) such as antibodies targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or the programmed cell death protein/programmed death ligand 1 (PD-1/PD-L1) axis. Experimental and clinical evidence show that immunotherapy based on immune checkpoint inhibitors (ICI) provides long-term survival benefits to cancer patients in whom other conventional therapies have failed. However, only a minority of patients show high clinical benefits via the use of ICI alone. One of the major factors limiting the clinical benefits to ICI can be attributed to the lack of immune cell infiltration within the tumor microenvironment. Such tumors are classified as “cold/warm” or an immune “desert”; those displaying significant infiltration are considered “hot” or inflamed. This review will provide a brief summary of different tumor properties contributing to the establishment of cold tumors and describe major strategies that could reprogram non-inflamed cold tumors into inflamed hot tumors. More particularly, we will describe how targeting hypoxia can induce metabolic reprogramming that results in improving and extending the benefit of ICI.

show abstract

Section: Strategies To Turn Non-inflamed Cold Tumors Into Inflamed Ho...mentioning

confidence: 99%

Lighting Up the Fire in the Microenvironment of Cold Tumors: A Major Challenge to Improve Cancer Immunotherapy

Benoit

Vogin

Duhem

et al. 2023

Cells

View full text Add to dashboard Cite

show abstract

“…Maintenance treatment period, the patients were treated with toripalimab 240 mg q6w continuously until the whole treatment cycle reached 1 year. The exact results of this study have not yet been published by the researchers, but they assumed the primary endpoint ORR would yield 80% (NCT05084677) ( 53 ).…”

Section: Anti-pd-1 Combined With Concurrent Chemoradiotherapy For Laccmentioning

confidence: 99%

“…q3w. Maintenance treatment period, the patients were Three modes of anti-PD-1 plus CCRT Anti-PD- (53).…”

Section: Toripalimab Combined With Ccrtmentioning

confidence: 99%

The anti-PD-1 era of cervical cancer: achievement, opportunity, and challenge

Li¹,

Cang²,

Gu³

et al. 2023

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

Cervical cancer is one of the three major female gynecological malignancies, becoming a major global health challenge. Although about 90% of early-stage patients can be cured by surgery, advanced-stage patients still need new treatment methods to improve their efficacy, especially for those with recurrence and metastasis tumors. Anti-PD-1 is currently the most widely used immune checkpoint inhibitor, which has revolutionized cancer therapy for different types of cancer. Pembrolizumab has been approved for second-line treatment of R/M CC but has a modest overall response rate of about 15%. Therefore, multiple types of anti-PD-1 have entered clinical trials successively and evaluated the efficacy in combination with chemotherapy, targeted therapy, and immunotherapy. At the same time, the dual specific antibody of PD-1/CTLA-4 was also used in clinical trials of cervical cancer, and the results showed better than anti-PD-1 monotherapy. In addition, anti-PD-1 has also been shown to sensitize radiotherapy. Therefore, understanding the current research progress of anti-PD-1 will better guide clinical application. This review summarizes ongoing clinical trials and published studies of anti-PD-1 monotherapy and combination therapy in the treatment of cervical cancer, as well as discusses the potential molecular biological mechanisms of combination, aiming to provide the basic evidence for support anti-PD-1 in the treatment of cervical cancer and new insights in combination immunotherapy.

show abstract

“…With the development and application of new technologies such as genomics, proteomics, and high-throughput sequencing, accurate gene diagnosis, targeted therapy [5], and immunotherapy [6] have become new models of tumor diagnosis and treatment. Especially, radiotherapy and chemotherapy combined with immune checkpoint inhibitor treatment in the treatment of recurrent or metastatic CC will trigger a huge revolution [7].…”

Section: Introductionmentioning

confidence: 99%

Development and validation of the integrative model and risk stratification based on deep learning and radiomics to predict survival of advanced cervical cancer patients

Guy,

Mao,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose Advanced cervical cancer (aCC) is aggressive and has a low 5-year survival rate. A novel integrative model needs to be developed to predict survival and guide clinical practice. Procedures: Patients were retrospectively studied from July 2014 to August 2016. The dataset was randomly split into training and validation cohorts. A deep learning model based on a Vision Transformer (ViT) and Recurrent Neural Network (RNN) was built to output a prognostic score (Rad-score) based on CT images. After combining Rad-score with clinical and pathological characteristics, Cox regression analysis was performed to establish the clinical model, radiomics model and integrative model, respectively, and the C-index was calculated. The time-dependent C-index curve, receiver operating characteristic (ROC) curve, calibration curve and decision curve analysis (DCA) were drawn to evaluate the performance of the model. Finally, a Nomogram was drawn to visualize the integrative model and develop the risk stratification. Results 396 patients were eventually enrolled in the study. The Cox regression analysis indicated that the Rad-score was an independent prognostic factor (HR = 4.06, 95% CI: 2.46–6.70, p < 0.001). Kaplan-Meier analysis showed that Rad-score allows significant risk stratification of patients. The integrative model achieved better performance in training (C-index: 0.784[0.733–0.835]) and validation cohorts (C-index: 0.726[0.677–0.785]) showed good survival prediction performance, which was superior to clinical model (training cohort: 0.686[0.625–0.747], validation cohort: 0.632[0.569–0.695]) and radiomics model (training cohort: 0.730[0.675–0.785], validation cohort: 0.723[0.658–0.788]). In addition, the ROC curve, time-dependent C-index curve, calibration curve and DCA curve of the integrative model all showed significant predictive performance advantages. Finally, the Nomogram visualized the survival prediction model. Kaplan-Meier curve showed the risk stratification had significant clinical value. Conclusions The integrative model and risk stratification based on Rad-score, clinical and pathological characteristics can be widely used in clinical practice to provide reliable clinical information for medical decisions.

show abstract

Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial

Cited by 5 publications

References 33 publications

Lighting Up the Fire in the Microenvironment of Cold Tumors: A Major Challenge to Improve Cancer Immunotherapy

Lighting Up the Fire in the Microenvironment of Cold Tumors: A Major Challenge to Improve Cancer Immunotherapy

The anti-PD-1 era of cervical cancer: achievement, opportunity, and challenge

Development and validation of the integrative model and risk stratification based on deep learning and radiomics to predict survival of advanced cervical cancer patients

Contact Info

Product

Resources

About